IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

PURPOSE: Irosustat is a first-generation, orally active, irreversible steroid sulfatase inhibitor. We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmieri, Carlo, Stein, Rob C., Liu, Xinxue, Hudson, Emma, Nicholas, Hanna, Sasano, Hironobu, Guestini, Fouzia, Holcombe, Chris, Barrett, Sophie, Kenny, Laura, Reed, Sadie, Lim, Adrian, Hayward, Larry, Howell, Sacha, Coombes, R. Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543190/
https://www.ncbi.nlm.nih.gov/pubmed/28612226
http://dx.doi.org/10.1007/s10549-017-4328-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543190/
https://www.ncbi.nlm.nih.gov/pubmed/28612226
http://dx.doi.org/10.1007/s10549-017-4328-z

Ejemplares similares